Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani

Journal of Immunology

Volumn 161, Issue 8, 1998, Pages 4153-4160

  Murphy, Michaela L ^a   Cotterell, Sara E J ^a   Gorak, Patricia M A ^a   Engwerda, Christian R ^a   Kaye, Paul M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4F10; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GRANULOMATOSIS; HOST RESISTANCE; INTRAPERITONEAL DRUG ADMINISTRATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOCONJUGATES; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032532640     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux Dosseto, M. Suzan, M. G. Mattei, and P. Golstein. 1987. A new member of the immunoglobulin superfamily: CTLA-4. Nature. 328:267.
2. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
3. Lindsten, T., K. P. Lee, E. S. Harris, B. Petryniak, N. Craighead, P. J. Reynolds, D. B. Lombard, G. J. Freeman, L. M. Nadler, G. S. Gray, et al. 1993. Characterization of CTLA-4 structure and expression on human T cells. J. Immunol. 151:3489.
4. Alegre, M. L., P. J. Noel, B. J. Eisfelder, E. Chuang, M. R. Clark, S. L. Reiner, and C. B. Thompson. 1996. Regulation of surface and intracellular expression of CTLA-4 on mouse T cells. J. Immunol. 157:4762.
5. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, and N. K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176:1595.
6. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1:405.
7. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1032.
8. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone. 1996. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 184:783.
9. Krummel, M. F., and J. P. Allison. 1995. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182:459.
10. Krummel, M. F., and J. P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533.
11. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270: 985.
12. Tivol, E. A., S. D. Boyd, S. McKeon, F. Borriello, P. Nickerson, T. B. Strom, and A. H. Sharpe. 1997. CTLA-4 Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158:5091.
13. Bluestone, J. A. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Immunol. 158:1989.
14. Perez, V. L., L. V. Parijs, A. Biuckians, X. X. Zheng, T. B. Strom, and A. K. Abbas. 1997. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411.
15. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734.
16. Kwon, E. D., A. A. Hurwitz, B. A. Foster, C. Madias, A. L. Feldhaus, N. M. Greenberg, M. B. Burg, and J. P. Allison. 1997. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94:8099.
17. Perrin, P. J., J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke. 1996. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1333.
18. McCoy, K., M. Camberis, and G. Le Gros. 1997. Protective immunity to nematode infection is induced by CTLA-4 blockade. J. Exp. Med. 186:183.
19. Murphy, M. L., C. R. Engwerda, P. M. A. Gorak, and P. M. Kaye. 1997. B7-2 blockade enhances T cell responses to Leishmania donovani. J. Immunol. 159: 4460.
20. Lucas, P. J., I. Negishi, K. I. Nakayama, L. E. Fields, and D. Y. Loh. 1995. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 154:5757.
21. Smelt, S. C., C. R. Engwerda, M. McCrossen, and P. M. Kaye. 1997. Destruction of follicular dendritic cells during chronic visceral leishmaniasis. J. Immunol. 158:3813.
22. Engwerda, C. R., S. C. Smelt, and P. M. Kaye. 1996. An in vivo analysis of cytokine production during Leishmania donovani infection in seid mice. Exp. Parasitol. 84:195.
23. Svetic, A., F. D. Finkleman, Y. C. Jian, C. W. Dieffenbach, D. E. Scott, K. F. McCarthy, A. D. Steinberg, and W. C. Gause. 1991. Cytokine gene expression after in vivo primary antibody immunization with goat antibody to mouse IgD antibody. J. Immunol. 147:2391.
24. Sonouchi, K., T. A. Hamilton, C. S. Tannenbaum, R. R. Tubbs, R. Bukowski, and J. H. Finke. 1994. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-α and interleukin-2. Am. J. Pathol 144:747.
25. Rhoades, E. R., A. M. Cooper, and I. M. Orme. 1995. Chemokine responses in mice infected with Mycobacterium tuberculosis. Infect. Immun. 63:3871.
26. Perkins, D., Z. Wang, C. Donovan, H. He, D. Mark, G. Guan, Y. Wang, T. Walunas, J. Bluestone, J. Listman, et al. 1996. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 156:4154.
27. Engwerda, C. R., M. L. Murphy, S. E. J. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669.
28. McElrath, M. J., H. W. Murray, and Z. A. Cohn. 1988. The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp. Med. 167:1927.
29. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-b7-1 and anti-b7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
30. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
31. Thompson, C. B., and J. P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445.
32. d) mouse strains. Infect. Immun. 57:2892.
33. Blackwell, J. M. 1983. Leishmania donovani infection in heterozygous and recombinant H-2 haplotype mice. Immunogenetics 18:101.
34. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R.G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFN-γ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231.
35. Murray, H. W., and J. Hariprashad. 1995. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J. Exp. Med. 181:387.
36. Murray, H. W., J. J. Stern, K. Welte, B. Y. Rubin, S. M. Carriero, and C. F. Nathan. 1987. Experimental visceral leishmaniasis: Production of interleukin 2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ. J. Immunol. 138:2290.
37. Murray, H. W. 1997. Endogenous interleukin 12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 175:1477.
38. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 143:4244.
39. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (TH2)-associated response model. J. Exp. Med. 185:867.
40. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322.
41. Kaye, P. M., A. Curry, and J. M. Blackwell. 1991. Differential production of Th1 and Th2 cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763.
42. Brown, D. R., J. M. Green, N. H. Moskowitz, M. Davis, C. B. Thompson, and S. L. Reiner. 1996. Limited role of CD28-mediated signals in T helper subset differentiation. J. Exp. Med. 184:803.
43. Hunter, C. A. 1996. How are NK cell responses regulated during infection? Exp. Parasitol. 84:444.
44. Hunter, C. A., L. Ellis Neyer, K. E. Gabriel, M. K. Kennedy, K. H. Grabstein, P. S. Linsley, and J. S. Remington. 1997. The role of the CD28/B7 interaction in the regulation of NK cell responses during infection with Toxoplasma gondii. J. Immunol. 158:2285.
45. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
46. Gorak, P. M. A., C. R. Engwerda, and P. M. Kaye. 1998. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur. J. Immunol. 28:687.
47. Tumang, M. C., C. Keogh, L. L. Moldawer, D. C. Helfgott, R. Teitelbaum, J. Hariprashad, and H. W. Murray. 1994. Role and effect of TNF-α in experimental visceral leishmaniasis. J. Immunol. 153:768.
48. Murray, H. W., K. E. Squires, C. D. Miralles, M. Y. Stoeckle, A. M. Granger, A. Granelli Piperno, and C. Bogdan. 1992. Acquired resistance and granuloma formation in experimental visceral leishmaniasis: differential T cell and lymphokine roles in initial versus established immunity. J. Immunol. 148:1858.
49. Herold, K. C., J. Lu, I. Rulifson, V. Vezys, D. Taub, M. J. Grusby, and J. A. Bluestone. 1997. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J. Immunol. 159:4150.
50. Moriuchi, H., M. Moriuchi, and A. S. Fauci. 1997. Nuclear factor-κ B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J. Immunol. 158:3483.
51. Kaye, P. M., N. J. Rogers, A. J. Curry, and J. C. Scott. 1994. Deficient expression of co-stimulatory molecules on Leishmania-infected macrophages. Eur. J. Immunol. 24:2850.
52. Lyons, B. A., and C. R. Parish. 1995. Are murine marginal-zone macrophages the splenic white pulp analog of high endothelial venules? Eur. J. Immunol. 25:3165.
53. + T helper cell subsets. Curr. Opin. Immunol. 5:391.
54. Kaye, P. M., P. Gorak, M. Murphy, and S. Ross 1995. Strategies for immune intervention in visceral leishmaniasis. Ann. Trop. Med. Parasitol. 89:S1 75.
55. Sundar, S., F. Rosenkaimer, M. L. Lesser, and H. W. Murray. 1995. Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-γ in visceral leishmaniasis. J. Infect. Dis. 171:992.
56. Sundar, S., and H. W. Murray. 1995. Effect of treatment with interferon-γ alone in visceral leishmaniasis. J. Infect. Dis. 172:1627.
57. Sundar, S., F. Rosenkaimer, and H. W. Murray. 1994. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-γ. J. Infect. Dis. 170:659.